Obagi Medical Products, Inc., a specialty pharmaceutical company, develops, markets, and sells topical aesthetic and therapeutic prescription skin care systems. It offers Obagi Nu-Derm System, which include prescription and OTC drugs that are used for the treatment of fine lines, wrinkles, acne, photo damage, hyperpigmentation, melasma, laxity, and skin sallowness; Obagi Condition and Enhance Systems used before and after surgical and non-surgical cosmetic procedures; Obagi-C Rx System that comprises Vitamin C with 4% hydroquinone system; and Professional-C products consisting of Vitamin C serums. The company also provides ELASTIderm Eye and Décolletage, which increases the elasticity and sk...
3760 Kilroy Airport Way
Long Beach, CA 90806
Founded in 1988
Suneva Medical, Inc. Announces Plans to Expand Existing Partnership with Obagi Medical Products
Oct 29 13
Suneva Medical, Inc. announced plans to expand its existing partnership with Obagi Medical Products, Inc. (Obagi). Suneva Medical distributes, and is the exclusive licensee for, the full line of ReGenica(R) skincare products, and Obagi currently co-distributes ReGenica Facial Rejuvenation Complex. Under the terms of the existing agreement between the two companies, Obagi will now co-distribute ReGenica Advanced Rejuvenation Day Repair and ReGenica Advanced Rejuvenation Overnight Repair.
Obagi Medical Products, Inc. Announces Executive Changes
Apr 26 13
On April 25, 2013, Odysseus Acquisition Corp. merged with and into Obagi Medical Products, Inc., with Obagi surviving the merger and continuing as a wholly-owned subsidiary of Valeant Pharmaceuticals International. In connection with the Merger, at the Effective Time, Albert F. Hummel, Albert J. Fitzgibbons, Ronald P. Badie, John A. Bartholdson, John H. Duerden, Howard A. Grant and Kristina M. Leslie resigned as directors of Obagi. Pursuant to the terms of the Merger Agreement, at the Effective Time the directors and officers of Purchaser immediately prior to the Effective Time became the directors and officers of Obagi following the Merger. Accordingly, as of April 25, 2013, Mr. Hummel, the Chief Executive Officer, Preston S. Romm, the Chief Financial Officer, David S. Goldstein, the Executive Vice President, Laura B. Hunter, the Vice President, General Counsel and Secretary, and Mark T. Taylor, the Senior Vice President, ceased being executive officers of Obagi and J. Michael Pearson assumed the role of director, President and Chief Executive Officer of Obagi, Howard B. Schiller assumed the role of director and Treasurer of Obagi and Robert R. Chai-Onn assumed the role of director and Secretary of Obagi. At the time Messrs. Schiller, Chai-Onn and Pearson assumed the role of director, it had not yet been determined which committees, if any, of the Board of Directors of Obagi on which Messrs. Schiller, Chai-Onn and Pearson would serve.
Obagi Medical Products, Inc.(NasdaqGS:OMPI) dropped from NASDAQ Composite Index
Apr 25 13
Obagi Medical Products, Inc. will be removed from NASDAQ Composite Index.